Evidence map›Paper›PMID 27425408›Full record

ArticleMolecular cell2016

An Autoinhibited Dimeric Form of BAX Regulates the BAX Activation Pathway.

Thomas P Garner, Denis E Reyna, Amit Priyadarshi, Hui-Chen Chen, Sheng Li, Yang Wu, Yogesh Tengarai Ganesan, Vladimir N Malashkevich, Emily H Cheng, Evripidis Gavathiotis

Erratum issuedOpen access · bronzeAbstract read
In one paragraph

Article in Molecular cell, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
5.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 103 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Mechanisms of BCL-2 family proteins in mitochondrial apoptosis.Nature reviews. Molecular cell biology · 2023
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Physiological and pharmacological modulation of BAX.Trends in pharmacological sciences · 2022
    Review
  17. Review
  18. Article
  19. BH3-mimetics: recent developments in cancer therapy.Journal of experimental & clinical cancer research : CR · 2021
    Review
  20. Protective and Anti-Inflammatory Effects of Protegrin-1 onInternational journal of molecular sciences · 2021
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Thomas P GarnerDepartment of Biochemistry and Department of Medicine, Albert Einstein Cancer Center, Wilf Family Cardiovascular Research Institute, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Denis E ReynaDepartment of Biochemistry and Department of Medicine, Albert Einstein Cancer Center, Wilf Family Cardiovascular Research Institute, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Amit PriyadarshiDepartment of Biochemistry and Department of Medicine, Albert Einstein Cancer Center, Wilf Family Cardiovascular Research Institute, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Hui-Chen ChenHuman Oncology and Pathogenesis Program and Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Sheng LiDepartment of Medicine and UCSD DXMS Proteomics Resource, University of California, San Diego, La Jolla, CA 92093, USA.
Yang WuDepartment of Biochemistry and Department of Medicine, Albert Einstein Cancer Center, Wilf Family Cardiovascular Research Institute, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Yogesh Tengarai GanesanHuman Oncology and Pathogenesis Program and Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Vladimir N MalashkevichDepartment of Biochemistry and Department of Biophysics and Physiology, Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Emily H ChengHuman Oncology and Pathogenesis Program and Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Evripidis GavathiotisDepartment of Biochemistry and Department of Medicine, Albert Einstein Cancer Center, Wilf Family Cardiovascular Research Institute, Albert Einstein College of Medicine, Bronx, NY 10461, USA. Electronic address: evripidis.gavathiotis@einstein.yu.edu.
Albert Einstein College of Medicine · USMemorial Sloan Kettering Cancer Center · USUniversity of California San Diego · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
WORD PROCESSORP30CA013330 · NCI · YESHIVA UNIVERSITY · PI THOMAS E ROHAN · 1985 to 2026
$111.2M
Core-010UL1TR001073 · NCATS · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI KELLER, MARLA J, SHAMOON, HARRY · 2013 to 2017
$21.3M
Life Science and Biomedical technology Research center at NSLS-II LSBRP41GM111244 · NIGMS · BROOKHAVEN SCIENCE ASSOC-BROOKHAVEN LAB · PI MCSWEENEY, SEAN · 2014 to 2018
$16.4M
Structure based design of antibodies and vaccinesU19AI117905 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI SCHIEF, WILLIAM R. · 2015 to 2019
$12.0M
ACTION OF LIPOLYTIC ENZYMESR01GM020501 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DENNIS, EDWARD A · 1985 to 2020
$7.3M
Mechanism of receptor-mediated entry and infection by filovirusesR01AI101436 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI CHANDRAN, KARTIK · 2012 to 2016
$4.0M
Small Molecule Activators of Pro-apoptotic BAX for Cancer TherapyR01CA178394 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI GAVATHIOTIS, EVRIPIDIS · 2014 to 2024
$3.7M
Apoptotic Network Integrated at the MitochondrionR01CA125562 · NCI · WASHINGTON UNIVERSITY · PI CHENG, EMILY H · 2007 to 2020
$3.4M
Targeting BAX Oligomerization in Hematologic DiseaseR00HL095929 · NHLBI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI GAVATHIOTIS, EVRIPIDIS · 2011 to 2013
$716k
Console and probe upgrade for 600 MHz NMRS10OD016305 · OD · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI COWBURN, DAVID · 2014 to 2014
$595k
NCATS NIH HHS UL1 TR001073NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA013330NCI NIH HHS R01 CA125562NCI NIH HHS R01 CA178394NHLBI NIH HHS R00 HL095929NIAID NIH HHS R01 AI101436NIAID NIH HHS U19 AI117905NIGMS NIH HHS P41 GM111244NIGMS NIH HHS R01 GM020501NIH HHS S10 OD016305
6 · The paper itself

Abstract

Pro-apoptotic BAX is a cell fate regulator playing an important role in cellular homeostasis and pathological cell death. BAX is predominantly localized in the cytosol, where it has a quiescent monomer conformation. Following a pro-apoptotic trigger, cytosolic BAX is activated and translocates to the mitochondria to initiate mitochondrial dysfunction and apoptosis. Here, cellular, biochemical, and structural data unexpectedly demonstrate that cytosolic BAX also has an inactive dimer conformation that regulates its activation. The full-length crystal structure of the inactive BAX dimer revealed an asymmetric interaction consistent with inhibition of the N-terminal conformational change of one protomer and the displacement of the C-terminal helix α9 of the second protomer. This autoinhibited BAX dimer dissociates to BAX monomers before BAX can be activated. Our data support a model whereby the degree of apoptosis induction is regulated by the conformation of cytosolic BAX and identify an unprecedented mechanism of cytosolic BAX inhibition.

Indexed as

ApoptosisSignal TransductionAnimalsbcl-2-Associated X ProteinBinding SitesCells, CulturedCrystallography, X-RayCytosolFibroblastsHumansMiceModels, MolecularProtein BindingProtein Conformation, alpha-HelicalProtein Interaction Domains and MotifsProtein MultimerizationBAX protein, humanBax protein, mousebcl-2-Associated X Protein

Identifiers

PMID27425408
PMCPMC4975667
OpenAlexW2463785236

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.